Neurocognitive Outcomes in HIV-Infected Children and Adolescents
Perinatally acquired HIV (PAH) infection was first described in 1981. Within a short time, it became clear that, as with adults, PAH could lead to devastating central nervous system damage in infants and children. Through the early years of the epidemic it also became clear that many infected infants had more subtle static neurocognitive deficits and behavioral disorders.
With the advent of effective antiretroviral therapies and earlier initiation of therapy for infected children, the incidence of more serious HIV-related neurocognitive effects decreased dramatically, and they are rarely seen today. In regions with access to effective pediatric antiretroviral therapy (ART), the vast majority of youth with PAH have learning and behavioral profiles similar to age and sociodemographically matched uninfected youth. With the ability now to achieve lifelong control of the infection, the hope is to develop treatment strategies that best ensure optimal long-term neurocognitive and...
KeywordsFatigue Toxicity Depression Cocaine Prednisone
- Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E., Rabie H, … CHER Study Team. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 2013;382:1555–63.Google Scholar
- Crowell CS, Yanling H, Tassiopoulos K, Malee KM, Yogev R, et al. … Pediatric HIV/AIDS Cohort Study (PHACS). Early viral suppression improves neurocognitive outcomes in HIV-infected children. AIDS 2015;29:295.Google Scholar
- Kapetanovic S, Leister E, Nichols S, Miller T, Tassiopoulos K et al. … & Pediatric HIV/AIDS Cohort Study Team. Relationships between markers of vascular dysfunction and neurodevelopmental outcomes in perinatally HIV-infected youth. AIDS 2010;24:1481.Google Scholar
- Laughton B, Cornell M, Grove D, Kidd M, Springer PE, Dobbels E, Janse Van Rensburg A, Violari A, Babiker AG, Madhi SA, Jean-Philippe P, Gibb DM, Cotton MF. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. AIDS 2012;26(13):1685–1690.Google Scholar
- Mellins CA, Tassiopoulos K, Malee K, Moscicki AB, Patton D, Pediatric HIV-AIDS Cohort Study, et al. Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and nonadherence to antiretroviral treatment. AIDS Patient Care STDs. 2011;25:413–22.CrossRefPubMedPubMedCentralGoogle Scholar
- Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage III GR, International Maternal Pediatric Adolescent AIDS Clinical Trials 219/219C Study Team. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. AIDS. 2009;23:1893–901.CrossRefPubMedPubMedCentralGoogle Scholar
- Puthanakit T, Ananworanich J, Vonthanak S, Kosalaraksa P, Hansudewechakul R, … and PREDICT Study Group. Cognitive function and neurodevelopmental outcomes in HIV-infected children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study. Pediatr Infect Dis J. 2013;32:501.Google Scholar